Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
44.98
+1.47 (3.38%)
Nov 22, 2024, 4:00 PM EST - Market closed
Kymera Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Cash & Equivalents | 110.72 | 109.97 | 68.4 | 47.98 | 31 | 76.02 | Upgrade
|
| Short-Term Investments | 439.25 | 264.92 | 338.77 | 394.44 | 265.2 | 15.94 | Upgrade
|
| Cash & Short-Term Investments | 549.97 | 374.88 | 407.17 | 442.42 | 296.2 | 91.96 | Upgrade
|
| Cash Growth | 53.70% | -7.93% | -7.97% | 49.36% | 222.11% | 122.87% | Upgrade
|
| Accounts Receivable | 1.32 | 18.76 | 2.54 | 0.14 | 1.43 | - | Upgrade
|
| Other Receivables | - | - | - | - | - | 0.29 | Upgrade
|
| Receivables | 1.32 | 18.76 | 2.54 | 0.14 | 1.43 | 0.29 | Upgrade
|
| Prepaid Expenses | 17.43 | 11.67 | 9.71 | 8.72 | 4.7 | 0.6 | Upgrade
|
| Total Current Assets | 568.72 | 405.32 | 419.42 | 451.27 | 302.34 | 92.85 | Upgrade
|
| Property, Plant & Equipment | 99.31 | 101.08 | 22.24 | 21.31 | 20.69 | 22.08 | Upgrade
|
| Long-Term Investments | 361.04 | 61.43 | 152.33 | 125.19 | 162.53 | - | Upgrade
|
| Other Long-Term Assets | 5.78 | 7.93 | 9.15 | 8.14 | 1.62 | 1.77 | Upgrade
|
| Total Assets | 1,035 | 575.76 | 603.13 | 605.91 | 487.18 | 116.7 | Upgrade
|
| Accounts Payable | 6.49 | 7.08 | 4.34 | 4.01 | 4.37 | 3.28 | Upgrade
|
| Accrued Expenses | 26.53 | 33.86 | 27.5 | 22.97 | 10.33 | 4.57 | Upgrade
|
| Current Portion of Leases | 12.85 | 6.35 | 3.94 | 3.6 | 3.26 | 3.38 | Upgrade
|
| Current Unearned Revenue | 20.02 | 37.88 | 35.26 | 61.74 | 92.55 | 23.35 | Upgrade
|
| Other Current Liabilities | 0.63 | 0.52 | 0.3 | 0.23 | 0.11 | - | Upgrade
|
| Total Current Liabilities | 66.53 | 85.69 | 71.34 | 92.54 | 110.62 | 34.57 | Upgrade
|
| Long-Term Leases | 75.38 | 78.33 | 13.39 | 14.36 | 14.73 | 17.82 | Upgrade
|
| Long-Term Unearned Revenue | - | 16.77 | 28 | 39.3 | 77.84 | 29.64 | Upgrade
|
| Other Long-Term Liabilities | - | - | 0.25 | 0.07 | 0.1 | - | Upgrade
|
| Total Liabilities | 141.91 | 180.79 | 112.98 | 146.27 | 203.29 | 82.03 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | - | Upgrade
|
| Additional Paid-In Capital | 1,575 | 926.27 | 878.88 | 689.28 | 412.78 | 2.04 | Upgrade
|
| Retained Earnings | -683.86 | -530.75 | -383.79 | -228.98 | -128.77 | -76.46 | Upgrade
|
| Comprehensive Income & Other | 1.93 | -0.55 | -4.95 | -0.66 | -0.13 | 0.01 | Upgrade
|
| Total Common Equity | 892.93 | 394.97 | 490.15 | 459.64 | 283.89 | -74.41 | Upgrade
|
| Shareholders' Equity | 892.93 | 394.97 | 490.15 | 459.64 | 283.89 | 34.67 | Upgrade
|
| Total Liabilities & Equity | 1,035 | 575.76 | 603.13 | 605.91 | 487.18 | 116.7 | Upgrade
|
| Total Debt | 88.23 | 84.67 | 17.34 | 17.96 | 17.99 | 21.19 | Upgrade
|
| Net Cash (Debt) | 822.77 | 351.64 | 542.16 | 549.64 | 440.74 | 70.76 | Upgrade
|
| Net Cash Growth | 132.44% | -35.14% | -1.36% | 24.71% | 522.83% | 74.45% | Upgrade
|
| Net Cash Per Share | 11.82 | 6.02 | 10.05 | 11.45 | 25.40 | 41.66 | Upgrade
|
| Filing Date Shares Outstanding | 64.77 | 61.11 | 55.18 | 51.67 | 44.81 | 1.93 | Upgrade
|
| Total Common Shares Outstanding | 64.75 | 55.59 | 55.04 | 51.5 | 44.48 | 1.93 | Upgrade
|
| Working Capital | 502.18 | 319.63 | 348.07 | 358.73 | 191.72 | 58.28 | Upgrade
|
| Book Value Per Share | 13.79 | 7.11 | 8.91 | 8.93 | 6.38 | -38.56 | Upgrade
|
| Tangible Book Value | 892.93 | 394.97 | 490.15 | 459.64 | 283.89 | -74.41 | Upgrade
|
| Tangible Book Value Per Share | 13.79 | 7.11 | 8.91 | 8.93 | 6.38 | -38.56 | Upgrade
|
| Machinery | 14.5 | 6.74 | 5.8 | 4.02 | 2.59 | 1.09 | Upgrade
|
| Leasehold Improvements | 44.01 | 7.8 | 7.8 | 7.74 | 7.6 | 0.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.